Insertional mutagenesis in gene therapy and stem cell biology

Current Opinion in Hematology

Volumn 14, Issue 4, 2007, Pages 337-342

  Baum, Christopher ^a,b  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b CINCINNATI CHILDREN S HOSPITAL RESEARCH FOUNDATION   (United States)

Author keywords

Gene therapy; Hematopoiesis; Integrase; Mutagenesis; Retrovirus

Indexed keywords

CELL THERAPY; CYTOLOGY; GENE INSERTION; GENE THERAPY; GENE VECTOR; HEMATOPOIESIS; HEMATOPOIETIC STEM CELL; HOMOLOGOUS RECOMBINATION; MUTAGENESIS; NONHUMAN; PRIORITY JOURNAL; REVIEW; STEM CELL;

ANIMALS; CLONE CELLS; GENE REGULATORY NETWORKS; GENE THERAPY; GENETIC VECTORS; HEMATOPOIETIC STEM CELLS; HUMANS; MUTAGENESIS, INSERTIONAL;

EID: 34249727198     PISSN: 10656251     EISSN: 15317048     Source Type: Journal    
DOI: 10.1097/MOH.0b013e3281900f01     Document Type: Review

References (44)

1. Li Z, Dullmann J, Schiedlmeier B, et al. Murine leukemia induced by retroviral gene marking. Science 2002; 296:497.
2. Modlich U, Kustikova O, Schmidt M, et al. Leukemias following retroviral transfer of multidrug resistance 1 are driven by combinatorial insertional mutagenesis. Blood 2005; 105:4235-4246.
3. Kustikova OS, Fehse B, Modlich U, et al. Clonal dominance of hematopoietic stem cells triggered by retroviral gene marking. Science 2005; 308:1171-1174.
4. Hacein-Bey-Abina S, Von Kalle C, Schmidt M, et al. LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. Science 2003; 302:415-419.
5. Baum C, Dullmann J, Li Z, et al. Side effects of retroviral gene transfer into hematopoietic stem cells. Blood 2003; 101:2099-2114.
6. Kohn DB, Sadelain M, Glorioso JC. Occurrence of leukaemia following gene therapy of X-linked SCID. Nat Rev Cancer 2003; 3:477-488.
7. Nienhuis AW, Dunbar CE, Sorrentino BP. Genotoxicity of retroviral integration in hematopoietic cells. Mol Ther 2006; 13:1031-1049. This report provides a comprehensive discussion of recent findings of insertional mutagenesis caused by retroviral vectors with important new conceptual contributions.
8. Ott MG, Schmidt M, Schwarzwaelder K, et al. Correction of X-linked chronic granulomatous disease by gene therapy, augmented by insertional activation of MDS1-EVI1, PRDM16 or SETBP1. Nat Med 2006; 12:401-409. This study is a milestone in the discovery of clonal imbalance in patients receiving gene-modified hematopoietic cells, revealing the yin (expansion of treated cells) and yang (potential induction of cell transformation) of insertional side effects, and emphasizing the relevance of the report by Kustikova et al. [3] for human gene therapy.
9. ••].
10. Gaspar HB, Parsley KL, et al. Gene therapy of X-linked severe combined immunodeficiency by use of a pseudotyped gammaretroviral vector. Lancet 2004; 364:2181-2187.
11. Aiuti A, Slavin S, Aker M, et al. Correction of ADA-SCID by stem cell gene therapy combined with nonmyeloablative conditioning. Science 2002; 296:2410-2413.
12. Gaspar HB, Bjorkegren E, Parsley K, et al. Successful reconstitution of immunity in ADA-SCID by stem cell gene therapy following cessation of PEG-ADA and use of mild preconditioning. Mol Ther 2006; 14:505-513. In an extension to the work reported by Aiuti et al. [11], this study underlines the promising therapeutic efficiency of gene therapy in a patient suffering from SCID-ADA, thus far without evidence of clonal imbalance.
13. Seggewiss R, Pittaluga S, Adler RL, et al. Acute myeloid leukemia associated with retroviral gene transfer to hematopoietic progenitor cells of a rhesus macaque. Blood 2006; 107:3865-3867. This is the first report of a malignant clonal expansion in a rhesus monkey transplanted with retrovirally modified hematopoietic cells. It challenges the previously established concept that a constitutive selective advantage mediated by the transgene product is an essential cofactor for malignant clonal expansion induced by insertional mutagenesis.
14. Du Y, Spence SE, Jenkins NA, Copeland NG. Cooperating cancer-gene identification through oncogenic-retrovirus-induced insertional mutagenesis. Blood 2005; 106:2498-2505.
15. Kustikova O, Geiger H, Li Z, et al. Retroviral vector insertion sites associated with dominant hematopoietic clones mark 'stemness' pathways. Blood 2007; 109:1897-1907. Confirming and extending the findings reported by Kustikova et al. [3], this study reveals that entire networks of stem cell-regulatory genes can be identified by insertional mutagenesis. Confirming and extending the findings reported by Du et al. [14], it also shows that insertion sites of retroviral vectors encoding oncogenes have a high likelihood of identifying potential cellular cooperation pathways.
16. Li Z, Kustikova O, Kamino K, et al. Insertional mutagenesis by replication-defective retroviral vectors encoding the large T oncogene. Ann NY Acad Sci 2007 [Epub ahead of print].
17. Schroder AR, Shinn P, Chen H, et al. HIV-1 integration in the human genome favors active genes and local hotspots. Cell 2002; 110:521-529.
18. Wu X, Li Y, Crise B, Burgess SM. Transcription start regions in the human genome are favored targets for MLV integration. Science 2003; 300:1749-1751.
19. Hematti P, Hong BK, Ferguson C, et al. Distinct genomic integration of MLV and SIV vectors in primate hematopoietic stem and progenitor cells. PLoS Biol 2004; 2:e423.
20. Trobridge GD, Miller DG, Jacobs MA, et al. Foamy virus vector integration sites in normal human cells. Proc Natl Acad Sci USA 2006; 103:1498-1503. This study reports on vectors derived from foamy virus vectors, and shows that their insertion profile is distinct from both HIV and MLV. It provides an excellent comparison with previously published studies.
21. Lewinski MK, Bushman FD. Retroviral DNA integration-mechanism and consequences. Adv Genet 2005; 55:147-181.
22. Lewinski MK, Yamashita M, Emerman M, et al. Retroviral DNA integration: viral and cellular determinants of target-site selection. PLoS Pathog 2006; 2:e60. This elegant study used hybrid viruses composed of modules derived from MLV and HIV to reveal that the viral integrase protein is the major determinant of the characteristic integration pattern observed in the different retroviruses. Other potential contributing factors such as cell cycling status or culture conditions appear to be less relevant.
23. Berry C, Hannenhalli S, Leipzig J, Bushman FD. Selection of target sites for mobile DNA integration in the human genome. PLoS Comput Biol 2006; 2:e157. This paper, which is not easy to digest for a non-bioinformatician, reveals that the choice of computational parameters may have a major impact on the results of bioinformatics studies of viral integration patterns.
24. Ehrhardt A, Engler JA, Xu H, et al. Molecular analysis of chromosomal rearrangements in mammalian cells after phiC31-mediated integration. Hum Gene Ther 2006; 17:1077-1094. This paper shows that the potentially sequence-specific integrase of the phage phiC31 may induce chromosomal aberrations.
25. •], however, the functional consequences of chromosomal aberrations remain unclear.
26. Urnov FD, Miller JC, Lee YL, et al. Highly efficient endogenous human gene correction using designed zinc-finger nucleases. Nature 2005; 435:646-651.
27. Alwin S, Gere MB, Guhl E, et al. Custom zinc-finger nucleases for use in human cells. Mol Ther 2005; 12:610-617.
28. Du Y, Jenkins NA, Copeland NG. Insertional mutagenesis identifies genes that promote the immortalization of primary bone marrow progenitor cells. Blood 2005; 106:3932-3939.
29. Modlich U, Bohne J, Schmidt M, et al. Cell-culture assays reveal the importance of retroviral vector design for insertional genotoxicity. Blood 2006; 108:2545-2553. This study converts the observations made by Du et al. [28] into a quantitative assay to detect differences in the transforming potential that depend on vector design.
30. Evans-Galea MV, Wielgosz MM, Hanawa H, et al. Suppression of clonal dominance in cultured human lymphoid cells by addition of the cHS4 insulator to a lentiviral vector. Mol Ther 2007; 15:801-809. This is the first reported evidence that genetic insulator elements may reduce the risk for insertional mutagenesis.
31. Montini E, Cesana D, Schmidt M, et al. Hematopoietic stem cell gene transfer in a tumor-prone mouse model uncovers low genotoxicity of lentiviral vector integration. Nat Biotechnol 2006; 24:687-696. This report introduces a tumor-prone mouse model to test the insertional genotoxicity of different integrating vectors.
32. Shou Y, Ma Z, Lu T, Sorrentino BP. Unique risk factors for insertional mutagenesis in a mouse model of XSCID gene therapy. Proc Natl Acad Sci USA 2006; 103:11730-11735. This study combines a tumor-prone mouse model with a mouse model of X-linked SCID to approach the mechanisms of leukemia induction observed in the clinical trial reported by Hacein-Bey-Abina et al. [4].
33. Pike-Overzet K, de Ridder D, Weerkamp F, et al. Ectopic retroviral expression of LMO2, but not IL2Rgamma, blocks human T-cell development from CD34+ cells: implications for leukemogenesis in gene therapy. Leukemia 2007; 21:754-763. This is a detailed analysis of the mechanisms of lymphoid cell transformation encountered in the context of gene therapy for X-linked SCID. The results reveal that insertional upregulation of the LMO2 proto-oncogene, and not the overexpression of the therapeutic gene product, alter lymphoid development.
34. Pike-Overzet K, de Ridder D, Weerkamp F, et al. Gene therapy: is IL2RG oncogenic in T-cell development? Nature 2006; 443:E5; discussion E6-7.
35. Thrasher AJ, Gaspar HB, Baum C, et al. Gene therapy: X-SCID transgene leukaemogenicity. Nature 2006; 443:E5-E6; discussion E6-7.
36. Woods NB, Bottero V, Schmidt M, et al. Gene therapy: therapeutic gene causing lymphoma. Nature 2006; 440:1123.
37. Engel BC, Podsakoff GM, Ireland JL, et al. Prolonged pancytopenia in a gene therapy patient with ADA-deficient SCID and trisomy 8 mosaicism: a case report. Blood 2007; 109:503-506. This somewhat provocative case report demonstrates the impact of pre-existing genetic lesions in cell and gene therapy.
38. Recchia A, Bonini C, Magnani Z, et al. Retroviral vector integration deregulates gene expression but has no consequence on the biology and function of transplanted T cells. Proc Natl Acad Sci USA 2006; 103:1457-1462. The authors report a careful analysis of retroviral vector insertion sites in human T cells studied both in vitro and after transplantation in patients. The study points to the potential of cell intrinsic or extrinsic factors that suppress the development of clonal imbalance in T cells, despite a potentially high frequency of cellular gene alterations by insertional mutagenesis.
39. Akagi K, Suzuki T, Stephens RM, et al. RTCGD: retroviral tagged cancer gene database. Nucleic Acids Res 2004; 32:D523-D527.
40. de Ridder J, Uren A, Kool J, et al. Detecting statistically significant common insertion sites in retroviral insertional mutagenesis screens. PLoS Comput Biol 2006; 2:e166. This study refines the mathematical approach to define 'common insertion sites' in mutagenesis studies.
41. Erkeland SJ, Verhaak RG, Valk PJ, et al. Significance of murine retroviral mutagenesis for identification of disease genes in human acute myeloid leukemia. Cancer Res 2006; 66:622-626. This study shows that insertional mutagenesis by replication-competent retroviruses in murine tumor models is relevant to human disease.
42. Pritsker M, Ford NR, Jenq HT, et al. Genome-wide gain-of-function genetic screen identifies functionally active genes in mouse embryonic stem cells. Proc Natl Acad Sci USA 2006; 103:6946-6951. Although not addressing hematopoietic stem cells, this study introduces an important approach to functional genomics.
43. Ivanova N, Dobrin R, Lu R, et al. Dissecting self-renewal in stem cells with RNA interference. Nature 2006; 442:533-538. An elegant approach is introduced to utilize RNA interference as a tool to identify genes that govern the self-renewal process of murine embryonic stem cells. This study has far-reaching implications for investigations addressing somatic stem cells.
44. Suzuki T, Minehata K, Akagi K, et al. Tumor suppressor gene identification using retroviral insertional mutagenesis in Blm-deficient mice. EMBO J 2006; 25:3422-3431. This paper introduces an elegant genetic model to screen tumor suppressor gene mutations caused by random insertion of replication-competent MLV. The approach may be applicable to test the risk for tumor suppressor gene mutation by gene vector integration.